Table 6 Change in patient-reported outcome measures and musculoskeletal involvement by the MCID estimates for all participants and for diffuse cutaneous SSc
Overall N | SF-36 PCS | SF-36 MCS | TDI | Joint contracturesb | Tendon friction rubsb | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
N | Mean difference | p valuea | N | Mean difference | p valuea | N | Mean difference | p valuea | N | N (% improved) | p value | N | N (% improved) | p value | ||
Change in mRSS > 5 improvement in diffuse cutaneous SSc | ||||||||||||||||
12 months | ||||||||||||||||
Change ≥ − 5 (no change/worsening group) | 82 | 62 | 0.59 (8.35) | Ref. | 62 | 1.79 (11.52) | Ref. | 76 | 0.32 (2.90) | Ref. | 53 | 2 (4%) | 0.01 | 12 | 9 (75%) | 0.99 |
Change <− 5 (improvement group) | 64 | 54 | 3.62 (8.20) | 0.05 | 54 | 3.05 (9.03) | 0.52 | 59 | 1.85 (4.03) | 0.01 | 40 | 9 (23%) | 12 | 9 (75%) | ||
Change in mRSS > 3 improvement in all participants | ||||||||||||||||
12 months | ||||||||||||||||
Change ≥ − 3 (no change/worsening group) | 143 | 102 | −0.01 (8.59) | Ref. | 102 | 0.90 (11.67) | Ref. | 132 | 0.04 (3.53) | Ref. | 61 | 7 (12%) | 0.3 | 8 | 5 (63%) | 0.33 |
Change <− 3 (improvement group) | 101 | 101 | 2.66 (8.11) | 0.03 | 85 | 3.27 (8.84) | 0.12 | 92 | 1.34 (3.72) | 0.01 | 56 | 10 (18%) | 18 | 15 (83%) | ||
Change in mRSS > 4 improvement in all participants | ||||||||||||||||
12 months | ||||||||||||||||
Change ≥ − 4 (no change/worsening group) | 159 | 115 | 0.05 (8.41) | Ref. | 115 | 1.37 (11.36) | Ref. | 144 | 0.03 (3.41) | Ref. | 68 | 7 (10%) | 0.1 | 12 | 9 (75%) | 0.99 |
Change <− 4 (improvement group) | 85 | 72 | 3.06 (8.26) | 0.02 | 72 | 2.93 (9.00) | 0.33 | 80 | 1.55 (3.90) | 0.01 | 49 | 10 (20%) | 14 | 11 (79%) | ||